89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

Source: Nasdaq GlobeNewswire / 27 Mar 2024 07:00:00   America/Chicago